Novartis AG ADR
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $13,334,986 | $14,358,000 | $14,836,000 | $13,620,000 |
Gross Profit | 9,793,255 | 10,819,000 | 11,514,000 | 10,393,000 |
EBITDA | 5,071,614 | 5,841,000 | 6,076,000 | 5,831,000 |
EBIT | 3,520,732 | 4,477,000 | 4,820,000 | 4,677,000 |
Net Income | 2,408,817 | 3,928,000 | 4,041,000 | 3,606,000 |
Net Change In Cash | 13,334,986 | 14,358,000 | 14,836,000 | 13,620,000 |
Free Cash Flow | 1,642,801 | 5,740,000 | 6,106,000 | 2,151,000 |
Cash | 11,435,020 | 9,556,000 | 6,656,000 | 7,066,000 |
Basic Shares | 1,929,000 | 1,940,000 | 1,960,000 | 1,979,000 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $54,811,252 | $51,722,000 | $46,660,000 | $43,461,000 |
Gross Profit | 41,121,506 | 38,895,000 | 34,188,000 | 31,879,000 |
EBITDA | 22,987,115 | 20,715,000 | 18,255,000 | 14,682,000 |
EBIT | 17,634,846 | 14,646,000 | 9,978,000 | 7,977,000 |
Net Income | 14,055,610 | 11,941,000 | 14,850,000 | 6,955,000 |
Net Change In Cash | 54,811,252 | 51,722,000 | 46,660,000 | 43,461,000 |
Free Cash Flow | 17,686,107 | 13,805,000 | 11,705,000 | 11,565,000 |
Cash | 11,435,020 | 11,459,000 | 13,393,000 | 7,517,000 |
Basic Shares | 1,955,000 | 2,035,000 | 2,092,000 | 2,197,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | $2.03 |
2025-09-30 | $2.25 |
2025-06-30 | $2.42 |
2025-03-31 | $2.28 |
